나눔터
공지사항
의학정보
복지정책
환우회소식
회비 및 후원금 납부내역
헌팅턴병 메뉴얼
HOME > 나눔터 > 의학정보

작성자
huntington [작성일 : 2016-09-23 15:48:40 ]   
제목 Teva 제약회사에서 진행중인 임상시험 소식을 전해드립니다.

신경보호효과 개선을 위한 약(Pridopidine)으로 현재 2임상시험 중에 있으며 헌팅턴병 증상을 늦추는 효과를 보인다고 합니다.


아직은 임상시험 단계인 약이며 추가 임상시험 단계등의 결과나오면 소식전해드리겠습니다.





Trial finds Teva drug could slow Huntington's disease

 

http://www.globes.co.il/en/article-teva-pridopidine-could-slow-huntingtons-d

isease-1001153229

 

Globes Correspondent 09/19/2016

 

 

 

Teva Pharmaceutical Industries Ltd. <http://www.tevapharm.com/>  today

announced what could be a major breakthrough in the treatment of

Huntington's Disease (HD) with positive results from its exploratory Phase

II PRIDE-HD study. The trial found a statistically significant impact on the

endpoint of the progression of Huntington Disease at 52 weeks following

treatment with Pridopidine at certain doses versus placebo. The effect of

Pridopidine was further evident in a sub-population of patients with early

stage HD, an effect first observed at 26 weeks.

 

 

 

"Slowing down the progression of this disease has proven to be impossible

until now. These findings give us a reason to believe we may be finally

making progress in slowing deterioration of disease," said Spyros

Papapetropoulos, Teva's VP Clinical Development, Neurodegenerative Diseases.

 

 

 

 

This was a 52-week, dose-ranging trial of Pridopidine twice daily versus

placebo, in the treatment of Huntington disease (HD). The study was directed

at measuring improvement in motor function and the effect on HD progression.

An unusually high placebo effect, extending beyond that expected from

previous studies, limited the ability to determine treatment effects on

assessments of HD motor scores. Evidence of symptomatic impact, however, was

seen in the early stage HD patient sub-population, with improvement in Total

Motor Score (TMS) and dystonia observed at 26 and 52 weeks in this patient

sub-set (stage 1 HD) at specific doses.

 

 

 

The discovery of Pridopidine's previously unknown mode of action as a potent

agonist of the Sigma 1 Receptor (S1R) resulted in a change in PRIDE-HD study

design, from a 26-week study focused on symptoms, to a 52-week study focused

on exploring pridopidine's potential impact on disease progression, as

measured by Total Functional Capacity (TFC).

 

 

 

"I am encouraged by these results, which provide us with clear insights into

the approach to be taken in Phase III development", said Michael Hayden,

President of Teva Global R&D and Chief Scientific Officer. "My obvious hope

is that this will provide the HD community with a medicine capable of

slowing down the progression of this devastating disease."

 

 

 

"These study results are very important for the HD community and for the

continued development of pridopidine. Firstly, pridopidine's safety profile

has been confirmed and extended. Secondly, we now have a clearer idea of the

dosages to study in Phase 3. Lastly, we have some of the most encouraging

evidence to date about an intervention which may slow the inexorable

functional decline of HD," said Karl Kieburtz, M.D., M.P.H., Director of the

Clinical & Translational Science Institute at the University of Rochester

Medical Center.

 

 

 

The results seen in this exploratory study will need to be confirmed in a

Phase III program that will be developed in collaboration with relevant

regulatory agencies.

 

 

 

Pridopidine is an investigational, oral small molecule being developed for

the treatment of HD that exerts its effect as an agonist of S1R. S1R plays a

key role in neuroprotection through increased production of brain-derived

neurotrophic factor (BDNF). Levels of BDNF are decreased in HD and other

neurodegenerative disorders including Parkinson's disease, Alzheimer's

disease and ALS.

 

================================

 

 

 

Huntington Study Group PRIDE HD Study Information:

http://huntingtonstudygroup.org/current-clinical-trials/pride-hd-study/

 

.       No information available yet on enrolling for the Phase 3 study.

 

.       No facilities in Florida participated in the Phase II study:

https://clinicaltrials.gov/ct2/show/study/NCT02006472?show_locs=Y#locn

 

[ 새글 | 답글 | 수정 | 삭제 ] [ 목록 ]
[ 총게시물 : 120 | page : 6 ]
[ 정렬조건 : 등록일 | 조회  ]
순번 제목 조회 파일 등록일 작성자
100   첫 번째 Huntingtin 저하 연구 간행물의 새로운 업데이트 489 20/06/10 운영자  
99   뇌를 감싼 액체에서 유해한 헌팅틴 단백질의 측정 459 20/07/30 운영자  
98   대규모 연구를 통한 헌팅턴병에서 새로운 유전적 변이(genetic modifie 475 20/07/10 운영자  
97   더 넓은 관점으로 본 헌팅턴병의 이상운동외 증상들 501 20/08/29 운영자  
96   전자빔이 헌팅턴병 단백질의 최상의 이미지를 보여준다. 443 20/08/06 운영자  
95   다소 긴 CAG 반복은 우리가 생각한 것보다 더 일반적이다 477 20/09/18 운영자  
94   지원시스템의 문제 발생 - 신경교세포가 헌팅턴병 증상에 관여한다 447 20/09/01 운영자  
93   Deutetrabenazine을 이용한 헌팅턴병 치료: 긍정적인 임상시험 그러나 500 20/10/19 운영자  
92   극도의 드문 돌변이가 뇌 발달에서 헌팅턴병 유전자의 중요성을 제시함 436 20/10/06 운영자  
91   죄송합니다 여러분, PRIDE-HD 임상시험에서 Pridopidine이 헌팅턴병의 442 20/11/29 운영자  
90   헌팅턴병의 차세대 게놈 편집 도구의 중요한 발전 437 20/11/06 운영자  
89   화이자의 아마릴리스 시험은 부정적 결과로 종료됨: 헌팅턴병의 증상 개... 430 18/12/16 운영자  
88   강력한 메시지: 독성 RNA 메시지 분자가 헌팅턴병에 해를 끼칠 수 있을 608 20/12/03 운영자  
87   예외도 쓸모가 있다 - 헌팅턴병의 발병 및 진행을 이해하기 위하여 예외... 437 21/01/19 운영자  
86   헌팅턴병을 통해 보여지는 세포 이동의 중요성 465 21/01/05 운영자  
85   헌팅틴이 망치를 들었다: 헌팅턴병에서 DNA 복구 506 21/02/24 운영자  
84   잘못된 진실: 대마초는 헌팅턴병을 향상시킬 수 있을까? 430 21/02/03 운영자  
83   무리를 이끄는 양 : 헌팅턴병에서 신진 대사 및 바이오 마커 426 21/03/19 운영자  
82   FDA 헌팅턴 질병의 증상에 대한 신약 승인 441 21/03/03 운영자  
81   게이트에 존재하는 적 –핵 수송을 방해하는 헌팅틴 452 21/04/22 운영자  

1 2 3 4 5 6 [ 새글 | 처음목록 | 목록 ]  
단체명 : 헌팅턴병 환우회   주소 : 서울시 종로구 연건동 서울대학교병원  

Copyrightⓒ by huntington.co.kr All rights reserved.    webmaster  개인정보 취급방침